ZA926122B - Process for the production of human protein containing preserved medicaments for infusion or injection purposes - Google Patents

Process for the production of human protein containing preserved medicaments for infusion or injection purposes

Info

Publication number
ZA926122B
ZA926122B ZA926122A ZA926122A ZA926122B ZA 926122 B ZA926122 B ZA 926122B ZA 926122 A ZA926122 A ZA 926122A ZA 926122 A ZA926122 A ZA 926122A ZA 926122 B ZA926122 B ZA 926122B
Authority
ZA
South Africa
Prior art keywords
preservative
human protein
prepn
infusion
sodium
Prior art date
Application number
ZA926122A
Other languages
English (en)
Inventor
Heinrich Woog
Werner Gruber
Hans Joerg Markl
Gerhard Winter
Fritz Demmer
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6438353&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA926122(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of ZA926122B publication Critical patent/ZA926122B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ZA926122A 1991-08-15 1992-08-14 Process for the production of human protein containing preserved medicaments for infusion or injection purposes ZA926122B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4126983A DE4126983A1 (de) 1991-08-15 1991-08-15 Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke

Publications (1)

Publication Number Publication Date
ZA926122B true ZA926122B (en) 1994-02-14

Family

ID=6438353

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA926122A ZA926122B (en) 1991-08-15 1992-08-14 Process for the production of human protein containing preserved medicaments for infusion or injection purposes

Country Status (25)

Country Link
US (2) US5503827A (ja)
EP (2) EP0607156B1 (ja)
JP (1) JP3670660B2 (ja)
KR (1) KR100263282B1 (ja)
AT (1) ATE145138T1 (ja)
AU (2) AU678756B2 (ja)
CA (1) CA2115348C (ja)
CZ (1) CZ284853B6 (ja)
DE (2) DE4126983A1 (ja)
DK (1) DK0607156T3 (ja)
ES (1) ES2094923T3 (ja)
FI (1) FI112169B (ja)
GE (1) GEP19981289B (ja)
GR (1) GR3022037T3 (ja)
HU (1) HU227421B1 (ja)
IL (1) IL102775A (ja)
MX (1) MX9204636A (ja)
NO (1) NO309844B1 (ja)
RU (1) RU2091068C1 (ja)
SG (1) SG66226A1 (ja)
SK (1) SK281910B6 (ja)
TW (1) TW351677B (ja)
UA (1) UA26343C2 (ja)
WO (1) WO1993003744A1 (ja)
ZA (1) ZA926122B (ja)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
JP3541054B2 (ja) * 1994-04-21 2004-07-07 ユニ・チャーム株式会社 使い捨ておむつ
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5888968A (en) * 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
EP0837883B1 (en) * 1995-06-07 2005-08-10 Chiron Corporation Method of solubilizing, purifying, and refolding protein
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU1747297A (en) * 1996-01-19 1997-08-11 Eli Lilly And Company Obesity protein formulations
JP2000504319A (ja) * 1996-01-19 2000-04-11 イーライ・リリー・アンド・カンパニー 肥満症タンパク質製剤
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6410511B2 (en) * 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DE19716154A1 (de) * 1997-04-18 1998-10-22 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren
ATE220558T1 (de) * 1997-11-22 2002-08-15 Roche Diagnostics Gmbh Verbessertes verfahren zur stabilisierung von proteinen
CA2312009A1 (en) * 1997-11-28 1999-06-10 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
KR100389726B1 (ko) * 1998-03-06 2003-06-27 쥬가이 세이야쿠 가부시키가이샤 안정한 과립구 콜로니-자극 인자 함유 제제
US20050203187A1 (en) * 1998-06-01 2005-09-15 Verbiscar Anthony J. Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
US6207718B1 (en) 1998-08-07 2001-03-27 Ontogeny, Inc. Pharmaceutical compositions containing hedgehog protein
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
HUP0201068A3 (en) * 1999-04-09 2002-10-28 Ortho Mcneil Pharm Inc Pharmaceutical compositions of erythropoietin
EE200200038A (et) 1999-07-22 2003-04-15 Aventis Pharmaceuticals Inc. Konservitud farmatseutilised preparaadid
CZ302750B6 (cs) * 1999-07-22 2011-10-19 Aventis Holdings Inc. Farmaceutická kompozice a ampulka na bázi erythropoietinu a zpusob inhibování mikrobiálního rustu v roztoku obsahujícím tuto látku
PT1129720E (pt) 2000-02-29 2004-08-31 Pfizer Prod Inc Factor estimulador de colonias de granulocitos estabilizado
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
AU2003235401B2 (en) * 2002-05-21 2008-09-25 Daiichi Sankyo Company, Limited Medicinal compositions containing ghrelin
SI21257A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin
US7812120B2 (en) * 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol
AU2003901515A0 (en) * 2003-04-02 2003-04-17 Norika Holdings Sterilisation process for pharmaceutical product
CA2528988C (en) * 2003-06-10 2012-05-01 Lg Life Sciences Ltd. Stable, aqueous solution of human erythropoietin, not containing serum albumin
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
EP1654283B1 (en) * 2003-08-13 2011-07-13 Novartis Vaccines and Diagnostics, Inc. Improved method of purifying tfpi and tfpi analogs
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
CA2576473C (en) * 2004-08-24 2015-06-30 Daiichi Asubio Pharma Co., Ltd. Liquid preparation of physiologically active peptide
CA2915270C (en) 2005-08-05 2017-07-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
DE102006009437A1 (de) * 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
EP2197919B1 (en) * 2007-08-27 2014-04-09 ratiopharm GmbH Liquid formulation of g-csf conjugate
JP2010536906A (ja) 2007-08-27 2010-12-02 バイオジェネリクス アーゲー Ｇ−ｃｓｆの液体製剤
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
PL2249869T3 (pl) * 2008-02-08 2012-02-29 Theramex Hq Uk Ltd Ciekły preparat FSH
US8120369B2 (en) 2009-03-02 2012-02-21 Harris Corporation Dielectric characterization of bituminous froth
CA2772220A1 (en) * 2009-09-25 2011-03-31 Santen Pharmaceutical Co. Ltd. Eye drops
WO2011095543A1 (en) 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
MA48047A (fr) * 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
US20210024936A1 (en) * 2018-04-09 2021-01-28 Board Of Regents, The University Of Texas System Therapeutic targeting of oncogenes using exosomes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3106073A1 (de) * 1981-02-19 1982-08-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von sterilen zubereitungen hochviskoser loesungen und substanzen
GB2177914B (en) * 1985-06-04 1989-10-25 Chugai Pharmaceutical Co Ltd A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
ATE121629T1 (de) * 1989-07-14 1995-05-15 Praxis Biolog Inc Stabile interleukine enthaltende impfstoffzusammensetzungen.
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions

Also Published As

Publication number Publication date
DE4126983A1 (de) 1993-02-18
FI112169B (fi) 2003-11-14
WO1993003744A1 (de) 1993-03-04
RU2091068C1 (ru) 1997-09-27
SK14894A3 (en) 1994-11-09
HU9400416D0 (en) 1994-05-30
AU1633997A (en) 1997-05-22
CA2115348C (en) 2007-07-17
CA2115348A1 (en) 1993-03-04
MX9204636A (es) 1993-02-01
NO940499L (no) 1994-02-14
CZ28794A3 (en) 1994-08-17
EP0607156A1 (de) 1994-07-27
DK0607156T3 (da) 1997-04-07
ES2094923T3 (es) 1997-02-01
GEP19981289B (en) 1998-05-01
SG66226A1 (en) 1999-07-20
TW351677B (en) 1999-02-01
AU678756B2 (en) 1997-06-12
AU2409492A (en) 1993-03-16
JP3670660B2 (ja) 2005-07-13
IL102775A (en) 1999-12-22
FI940674A (fi) 1994-02-14
KR100263282B1 (ko) 2000-08-01
FI940674A0 (fi) 1994-02-14
IL102775A0 (en) 1993-01-31
DE59207523C5 (de) 2006-11-16
NO940499D0 (no) 1994-02-14
JPH06510031A (ja) 1994-11-10
CZ284853B6 (cs) 1999-03-17
RU94016163A (ru) 1996-08-10
HUT67379A (en) 1995-04-28
HU227421B1 (en) 2011-05-30
GR3022037T3 (en) 1997-03-31
UA26343C2 (uk) 1999-08-30
US5503827A (en) 1996-04-02
NO309844B1 (no) 2001-04-09
ATE145138T1 (de) 1996-11-15
DE59207523D1 (de) 1996-12-19
US6303113B1 (en) 2001-10-16
EP0528313A1 (de) 1993-02-24
AU710768B2 (en) 1999-09-30
EP0607156B1 (de) 1996-11-13
SK281910B6 (sk) 2001-09-11

Similar Documents

Publication Publication Date Title
ZA926122B (en) Process for the production of human protein containing preserved medicaments for infusion or injection purposes
CS274681B2 (en) Method of erythropoietin's stabilized preparation production
EP0299756A3 (en) Anti-acne composition
FI875308A0 (fi) Foerfarande i tvao steg foer att hela ett saor smaertfritt och ett vattenhaltigt medium och en salva foer lokal anvaendning vid foerfarandet.
DE219220T1 (de) Verfahren und zusammensetzung zur gleichzeitigen reinigung und desinfektion von kontaktlinsen.
EP0747092A3 (en) Dissolution liquid for drug in iontophoresis
ES445542A1 (es) Procedimiento de obtencion de laminas de recubrimiento para aplicaciones cosmeticas.
GB1450598A (en) Insuling preparations
JPS57128635A (en) Pharmaceutical preparation of gamma-globulin for venoclysis
IT1243742B (it) Composizioni farmaceutiche a base di calcitonine
FR2185416A1 (en) Isotonic injectable ACTH compsns - with low content of polyphloretin phosphate, but with prolonged activity
van Bruchem Abomasal mucosal bloodflow in relation to abomasal seretory activity in sheep
IT1206281B (it) Attivatore del plasminogeno dei tessuti e suo impiego nella medicina umana ed in veterinaria
PT82277A (en) Method for enhancement of absorption of proteins with medicinal properties